Evidence map›Paper›PMID 12595843›Full record

Trial reportAmerican heart journal2003

Angiographic changes in saphenous vein grafts are predictors of clinical outcomes.

Genell L Knatterud, Carl White, Nancy L Geller, Lucien Campeau, Sandra A Forman, Michael Domanski, James S Forrester, Fredarick L Gobel, J Alan Herd, Ann Hickey and 4 more

Registry-linked trialAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in American heart journal, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03542110 (Effect of Alirocumab on Saphenous Vein Graft Atherosclerosis), which is not on this map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03542110 phase4terminatedstarted 2018, after this paper: background citation

Effect of Alirocumab on Saphenous Vein Graft Atherosclerosis: The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial

Ran2018Enrolled46Registered outcomes4Posted comparisons0ConditionsSaphenous Vein Graft AtherosclerosisArmsAlirocumab 150 MG/ML subcutaneous injection, Matching Placebo subcutaneous injection
Open the trial in the graph
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Impact of Graft Velocity on Saphenous Vein Graft Atherosclerosis after Coronary Artery Bypass Grafting.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2024
    Trial
  4. Article
  5. Coronary Artery Bypass Graft Degenerative Disease.Current treatment options in cardiovascular medicine · 2001
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Genell L KnatterudMaryland Medical Research Institute, Baltimore, MD 21210, USA. gknatterud@mmri.org
Carl White
Nancy L Geller
Lucien Campeau
Sandra A Forman
Michael Domanski
James S Forrester
Fredarick L Gobel
J Alan Herd
Ann Hickey
Byron J Hoogwerf
Donald B Hunninghake
Michael L Terrin
Yves Rosenberg
Baltimore City Health Department · US

Funding

POST CORONARY ARTERY BYPASS GRAFT STUDYN01HC075076 · HC · MARYLAND MEDICAL RESEARCH INSTITUTE, INC · PI KNATTERUD, GENELL L · 1987 to 1999
–
NHLBI NIH HHS N01-HC-75076
6 · The paper itself

Abstract

backgroundPrevious studies have suggested that angiographic evidence of disease progression in coronary arteries increases the risk of subsequent coronary clinical events. This study ascertained whether patients enrolled in the Post Coronary Artery Bypass Graft Clinical Trial (POST CABG) who had substantial progression of atherosclerosis in >or=1 saphenous vein grafts (on the basis of assessment of baseline and follow-up angiograms obtained 4-5 years after study entry), but who had not reported clinical symptoms before follow-up angiography, were at a higher risk of subsequent events than patients who did not have substantial progression of atherosclerosis (decrease >or=0.6 mm in lumen diameter at site of greatest change from baseline).

methodsAll 1351 patients enrolled in the trial underwent baseline angiography; only the 961 patients who had follow-up angiography and no coronary events before the follow-up study were included in this analysis. The clinical center staff contacted patients to ascertain the events that had occurred after follow-up angiography (approximately 3.4 years later).

resultsSixty-nine patients had died; 870 patients or relatives were interviewed, and 22 patients could not be contacted. Univariable estimates of relative risk associated with substantial progression ranged from 2.2 (P <.001) for cardiovascular death or nonfatal myocardial infarction to 3.3 (P <.001) for revascularization. Multivariable and univariable estimates of risk were similar.

conclusionsThe findings provide evidence that patients who had substantial progression of atherosclerosis in vein grafts are at an increased risk for subsequent coronary events and suggest that angiographic changes in vein grafts are appropriate surrogate measures for clinical outcomes.

Indexed as

AgedAnalysis of VarianceCoronary AngiographyCoronary Artery DiseaseDisease ProgressionFemaleGraft Occlusion, VascularHumansMaleMiddle AgedMyocardial RevascularizationPrognosisRiskSaphenous VeinTreatment Outcome

Identifiers

PMID12595843
OpenAlexW2084163379

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.